Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bob T Li

Showing results (1-10 of 139) with videos related to

Pageof 14
Sort By:
Nature Medicine|April 18, 2024
Targeting KRAS in cancerAnupriya Singhal, Bob T Li, Eileen M O'Reilly
Journal of Clinical Medicine|August 4, 2015
Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical PracticeBob T Li, Matthew H Wong, Nick Pavlakis
The Journal of Thoracic and Cardiovascular Surgery|April 5, 2018
Circulating tumor DNA: A promising biomarker to guide postoperative treatment and surveillance of non-small cell lung cancerJames M Isbell, David R Jones, Bob T Li
The Journal of Thoracic and Cardiovascular Surgery|June 20, 2021
The emerging role of local therapy in oligometastatic non-small cell lung cancerJames M Isbell, Bob T Li, Daniel R Gomez
The New England Journal of Medicine|May 4, 2022
Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer. ReplyBob T Li, Egbert F Smit, Pasi A Jänne
Journal of Thoracic Disease|January 12, 2019
Liquid biopsy guided precision therapy for lung cancersChongrui Xu, Michael Offin, Paul K Paik, et al.
Annals of Translational Medicine|June 9, 2016
What does the future hold for immunotherapy in cancer?Jarushka Naidoo, Bob T Li, Katja Schindler, et al.
Cancer|April 2, 2025
Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategiesDaniel Reinhorn, Mor Moskovitz, William D Tap, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 6, 2024
A Promising Step Forward With Giant Leaps AheadNarek Shaverdian, Bob T Li, James Isbell, et al.
Therapeutics and Clinical Risk Management|July 28, 2018
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of <i>NTRK</i>, <i>ROS1</i>, and <i>ALK</i> fusion-positive solid tumorsDazhi Liu, Michael Offin, Stephen Harnicar, et al.
Pageof 14

Showing results (1-10 of 139) with videos related to

Sort By:
Pageof 14
Nature Medicine|April 18, 2024
Targeting KRAS in cancerAnupriya Singhal, Bob T Li, Eileen M O'Reilly
Journal of Clinical Medicine|August 4, 2015
Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical PracticeBob T Li, Matthew H Wong, Nick Pavlakis
The Journal of Thoracic and Cardiovascular Surgery|April 5, 2018
Circulating tumor DNA: A promising biomarker to guide postoperative treatment and surveillance of non-small cell lung cancerJames M Isbell, David R Jones, Bob T Li
The Journal of Thoracic and Cardiovascular Surgery|June 20, 2021
The emerging role of local therapy in oligometastatic non-small cell lung cancerJames M Isbell, Bob T Li, Daniel R Gomez
The New England Journal of Medicine|May 4, 2022
Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer. ReplyBob T Li, Egbert F Smit, Pasi A Jänne
Journal of Thoracic Disease|January 12, 2019
Liquid biopsy guided precision therapy for lung cancersChongrui Xu, Michael Offin, Paul K Paik, et al.
Annals of Translational Medicine|June 9, 2016
What does the future hold for immunotherapy in cancer?Jarushka Naidoo, Bob T Li, Katja Schindler, et al.
Cancer|April 2, 2025
Targeting HER2 in lung cancers: Evolving treatment landscape and drug development strategiesDaniel Reinhorn, Mor Moskovitz, William D Tap, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 6, 2024
A Promising Step Forward With Giant Leaps AheadNarek Shaverdian, Bob T Li, James Isbell, et al.
Therapeutics and Clinical Risk Management|July 28, 2018
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of <i>NTRK</i>, <i>ROS1</i>, and <i>ALK</i> fusion-positive solid tumorsDazhi Liu, Michael Offin, Stephen Harnicar, et al.
Pageof 14